We are live on ! Find out more
COGT icon

Cogent Biosciences

135 hedge funds and large institutions have $886M invested in Cogent Biosciences in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 58 increasing their positions, 36 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

242% more call options, than puts

Call options by funds: $940K | Put options by funds: $275K

61% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 36

20.62% more ownership

Funds ownership: 85.69%106.31% (+21%)

0% more funds holding in top 10

Funds holding in top 10: 77 (0)

1% less funds holding

Funds holding: 136135 (-1)

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

15% less capital invested

Capital invested by funds: $1.05B → $886M (-$162M)

Holders
135
Holders Change
-1
Holders Change %
-0.74%
% of All Funds
2.14%
Holding in Top 10
7
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
12
Increased
58
Reduced
36
Closed
13
Calls
$940K
Puts
$275K
Net Calls
+$665K
Net Calls Change
+$444K
Name Holding Trade Value Shares
Change
Change in
Stake
PHP
51
Parkman Healthcare Partners
Connecticut
$1.89M +$93.2K +7,855 +4%
Rafferty Asset Management
52
Rafferty Asset Management
New York
$1.87M -$170K -14,366 -7%
Bank of America
53
Bank of America
North Carolina
$1.39M -$38.6K -3,257 -2%
IBT
54
International Biotechnology Trust
United Kingdom
$1.31M +$1.6M +135,000 New
Morgan Stanley
55
Morgan Stanley
New York
$1.26M -$506K -42,676 -25%
Balyasny Asset Management
56
Balyasny Asset Management
Illinois
$1.22M +$1.49M +125,638 New
Millennium Management
57
Millennium Management
New York
$1.21M -$5.89M -496,327 -80%
WP
58
Woodline Partners
California
$1.17M +$1.42M +120,000 New
Swiss National Bank
59
Swiss National Bank
Switzerland
$1.15M
RhumbLine Advisers
60
RhumbLine Advisers
Massachusetts
$1.11M +$162K +13,679 +14%
Barclays
61
Barclays
United Kingdom
$1.08M -$17.6K -1,481 -1%
D.E. Shaw & Co
62
D.E. Shaw & Co
New York
$1.08M -$1.09M -91,630 -45%
SG Americas Securities
63
SG Americas Securities
New York
$1.02M +$781K +65,843 +169%
AG
64
Algert Global
California
$1M -$8.3K -700 -0.7%
DekaBank Deutsche Girozentrale
65
DekaBank Deutsche Girozentrale
Germany
$833K
CS
66
Credit Suisse
Switzerland
$817K +$49.8K +4,201 +5%
Citigroup
67
Citigroup
New York
$802K +$29.9K +2,522 +3%
UBS Group
68
UBS Group
Switzerland
$771K -$40.3K -3,401 -4%
AllianceBernstein
69
AllianceBernstein
Tennessee
$704K
Fisher Asset Management
70
Fisher Asset Management
Washington
$669K
California State Teachers Retirement System (CalSTRS)
71
California State Teachers Retirement System (CalSTRS)
California
$642K -$57.1K -4,818 -7%
IC
72
Ikarian Capital
Texas
$612K
Citadel Advisors
73
Citadel Advisors
Florida
$591K -$880K -74,162 -55%
Legal & General Group
74
Legal & General Group
United Kingdom
$530K +$5.21K +439 +0.8%
Wells Fargo
75
Wells Fargo
California
$516K -$113K -9,488 -15%

COGT Hedge Fund Activity: Q3 2023 in Review

135 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q3 2023, worth a combined $886M — down 15% from $1.05B a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of COGT and 12 opened new positions — a net loss of 1 holder — while 36 trimmed existing stakes and 58 added.

The largest buyer was Fidelity Investments, adding an estimated $50.4M. The largest seller was Deerfield Management, cutting an estimated $27M.

  • 135 institutional investors held Cogent Biosciences (COGT) as of Q3 2023, down from 136 in Q2 2023.
  • Funds reported $886M of Cogent Biosciences stock for Q3 2023, down 15% quarter-over-quarter.
  • 12 funds opened new Cogent Biosciences positions in Q3 2023 and 13 closed out, a net change of -1 holder.
  • The largest Cogent Biosciences buyer in Q3 2023 was Fidelity Investments, an estimated $50.4M added.
  • The largest Cogent Biosciences seller in Q3 2023 was Deerfield Management, an estimated $27M sold.

Based on aggregated 13F filings for Q3 2023.